Search Results for: FGFR2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ELK4 ETS transcription factor ELK4
  • Prostate cancer
Novel MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
  • Penile cancer
  • Alveolar rhabdomyosarcoma
Novel MGMT O-6-methylguanine-DNA methyltransferase
  • MGMT-mediated DNA damage reversal
  • Cysteine
  • Zinc
  • S-Methylcysteine
  • S-Benzylcysteine
  • Dinitrochlorobenzene
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Novel OAT ornithine aminotransferase
  • Glutamate and glutamine metabolism
  • Pyridoxal phosphate
  • Ornithine
  • Gabaculine
  • Canaline
  • Ornithinaemia
Novel PLSCR1 phospholipid scramblase 1
Novel PLXNA1 plexin A1
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Other semaphorin interactions
Novel PTPRE protein tyrosine phosphatase receptor type E
  • Alendronic acid
  • Tiludronic acid
Novel SEC23IP SEC23 interacting protein
  • COPII-mediated vesicle transport
ANOS1 anosmin 1
  • FGFR1c ligand binding and activation
  • Negative regulation of FGFR1 signaling
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Alzheimer's disease (AD)
BEX1 brain expressed X-linked 1
BEX2 brain expressed X-linked 2
CACNA1D calcium voltage-gated channel subunit alpha1 D
  • Adrenaline,noradrenaline inhibits insulin secretion
  • NCAM1 interactions
  • Regulation of insulin secretion
  • Regulation of insulin secretion
  • Ergocalciferol
  • Enflurane
  • Ranolazine
  • Phenytoin
  • Isradipine
  • Topiramate
  • Nimodipine
  • Nisoldipine
  • Spironolactone
  • Cinnarizine
  • Nicardipine
  • Magnesium sulfate
  • Levomenthol
  • Ethanol
  • Felodipine
  • Nitrendipine
  • Miconazole
  • Nifedipine
  • Amiodarone
  • Mibefradil
  • Dronedarone
  • Clevidipine
  • Nilvadipine
  • Trimebutine
  • Aranidipine
  • Benidipine
  • Cilnidipine
  • Lacidipine
  • Levamlodipine
  • Manidipine
  • Butamben
  • Bioallethrin
  • Bioallethrin
  • Fish oil
CTDSP1 CTD small phosphatase 1
  • Aspartate beryllium trifluoride
  • Citric acid
CTDSPL CTD small phosphatase like
DUSP14 dual specificity phosphatase 14
EPHA4 EPH receptor A4
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
ERRFI1 ERBB receptor feedback inhibitor 1
FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)

Page 1 out of 3 pages